256397-12-3

Upstream product

• 256397-61-2 6-methyl-4'-trifluoromethyl-1,1'-biphenyl-2-carboxylic acid 
• 256397-60-1 6-methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid methyl ester 
• 256397-59-8 (S)-(5-amino-2,3-dihydro-1H-inden-2-yl)carbamic acid methyl ester 
• 256397-64-5 [6-METHYL-4'-(TRIFLUOROMETHYL)-[1, 1'-BIPHENYL]-2-CARBONYL] 

Downstream Products

• 351415-08-2 [1,1'-biphenyl]-2-carboxamide, N-[(2S)-2-amino-2,3-dihydro-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- 
• 954410-40-3 C₂₈H₂₄F₃N₃OS 
• 1103433-30-2 C₃₂H₂₉F₃N₂O 
• 1103433-31-3 C₃₂H₂₆F₆N₂O 

Relevant academic research and scientific papers

Identification and structure-activity relationships of ortho-biphenyl carboxamides as potent Smoothened antagonists inhibiting the Hedgehog signaling pathway

Ortho-biphenyl carboxamides, originally prepared as inhibitors of microsomal triglyceride transfer protein (MTP) have been identified as novel inhibitors of the Hedgehog signaling pathway. Structure-activity relationship studies for this class of compound

Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals

The invention relates to the use of fibrates for lowering the liver toxicity of MTP inhibitors as well as pharmaceutical compositions containing an MTP inhibitor and a fibrate.

Diaminoindanes as microsomal triglyceride transfer protein inhibitors

The synthesis and biological activities of biarylamide-substituted diaminoindanes as microsomal triglyceride transfer protein (MTP) inhibitors are described. One of the more potent compounds, 8aR, inhibited both the secretion of apoB from Hep G2 cells and the MTP-mediated transfer of triglycerides between synthetic acceptor and donor liposomes with IC50 values of 0.7 and 70 nM, respectively. In normolipidemic rats and dogs, oral administration of 8aR dose-dependently reduced both plasma triglycerides and total cholesterol. Moreover, in rats and dogs, 8aR also prevented the postprandial rise in plasma triglycerides following a bolus administration of a fat load. Because MTP inhibitors decrease very low density lipoprotein assembly in the liver, the potential for hepatic lipid accumulation was evaluated. In normolipidemic rats, hepatic cholesterol and triglyceride contents were dose-dependently increased by 8aR. However, hepatic lipid accumulation resulted in negligible change in total liver weight and was reversible after withdrawal of the compound.